Press Releases
September 23, 2020
Published by Adelle McGourty at September 23, 2020
Categories
Data from Phase IIa show potent effect of Epeleuton on Triglyceride and HbA1C levels Dublin, Ireland, 23rd September 2020 – Afimmune, a clinical stage drug discovery […]
August 11, 2020
Published by micadmin at August 11, 2020
Categories
The Epeleuton Phase 2a data was accepted for publication in the peer reviewed Journal of the American Heart Association. The paper can be found here. In […]
November 14, 2019
Published by Adelle McGourty at November 14, 2019
Categories
Dublin, Ireland, 14th November 2019 – Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at […]
December 18, 2018
Published by Adelle McGourty at December 18, 2018
Categories
Dublin, Ireland, 18th December 2018 – Afimmune, a privately held clinical stage drug discovery and development company, today announced receipt of allowance for a patent application in […]
October 18, 2017
Published by micadmin at October 18, 2017
Categories
Dublin, Ireland, 18th October 2017 – Afimmune (AF), a privately held drug discovery and development company, today announced receipt of allowance for a patent application in […]
March 29, 2017
Published by Linda Connolly at March 29, 2017
Categories
Dublin, Ireland, 29th March 2017: Afimmune, a privately held biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted fast track […]
April 14, 2016
Published by micadmin at April 14, 2016
Categories
Dublin, Ireland, 14th April 2016: Afimmune is today presenting a late-breaking news abstract at the annual meeting of the EASL International Liver Congress in Barcelona, Spain […]
December 18, 2015
Published by micadmin at December 18, 2015
Categories
Dublin, Ireland, December 18th, 2015 – Afimmune, a privately held biopharmaceutical company, today announced the successful completion of a Phase I trial with an oral formulation […]
November 9, 2015
Published by micadmin at November 9, 2015
Categories
Dublin, Ireland, November 9th, 2015 – Afimmune, a privately held biopharmaceutical company, announced today that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 […]
January 5, 2015
Published by micadmin at January 5, 2015
Categories
Afimmune today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis (NASH). DS102 […]